UTHR logo

United Therapeutics Corporation (UTHR)

$584.10

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on UTHR

Market cap

$24.88B

EPS

26.46

P/E ratio

26.6

Price to sales

9.93

Dividend yield

--

Beta

0.483887

Price on UTHR

Previous close

$587.88

Today's open

$584.96

Day's range

$575.41 - $590.94

52 week range

$455.63 - $614.23

Profile about UTHR

CEO

Martine Rothblatt

Employees

1400

Headquarters

Silver Spring, MD

Exchange

Nasdaq Global Select

Shares outstanding

42588726

Issue type

Common Stock

UTHR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on UTHR

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter

United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory and clinical milestones at the UBS London Healthcare Conference.

news source

MarketBeat • Nov 17, 2026

news preview

United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript

United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or United Therapeutics (UTHR).

news source

Zacks Investment Research • Nov 16, 2026

news preview

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor conferences in London. UBS Global Biopharma Conference on Monday, November 16, 2026, from 10:00 a.m. to 10:30 a.m., GMT. Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, from 2:00 p.m. to 2:25 p.m.

news source

Business Wire • Nov 9, 2026

news preview

What United Therapeutics (UTHR) Said on Its Q3 Earnings Call

United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission for its soft mist inhaler to 2027.

news source

MarketBeat • Nov 4, 2026

news preview

United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025. “United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies.

news source

Business Wire • Nov 4, 2026

news preview

United Therapeutics (UTHR) Q3 Earnings Miss Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in United Therapeutics Corporation

Open an M1 investment account to buy and sell United Therapeutics Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in UTHR on M1